News
CHRS
2.390
-1.24%
-0.030
Weekly Report: what happened at CHRS last week (0318-0322)?
Weekly Report · 3d ago
Coherus Biosciences: Dumping One Drug But Showing Promise With Another
Coherus Biosciences has sold Cimerli, a Lucentis biosimilar, to Sandoz for $170M. CHRS has a new drug and a developmental pipeline. The company's anti-IL-27 antibody, casdozokitug, shows promising results in hepatocellular carcinoma. I upgrade my rating from hold to buy for Coherus.
Seeking Alpha · 03/21 00:14
Coherus BioSciences Price Target Cut to $11.00/Share From $13.00 by HC Wainwright & Co.
Dow Jones · 03/20 11:28
Coherus BioSciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/20 11:28
HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $11
Benzinga · 03/20 11:19
Buy Rating on Coherus Biosciences: Balancing Divestiture with Promising Pipeline and Financial Growth
TipRanks · 03/20 10:16
Weekly Report: what happened at CHRS last week (0311-0315)?
Weekly Report · 03/18 10:03
Coherus Biosciences: Strong Q4 Performance and Strategic Moves Merit Outperform Rating
TipRanks · 03/15 05:36
Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Solid Biosciences (SLDB)
TipRanks · 03/15 00:30
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Coherus Biosciences (CHRS) and Autolus Therapeutics (AUTL)
TipRanks · 03/14 17:40
Coherus gains as oncology focus leads to job cuts
generic drugmaker Coherus BioSciences (NASDAQ:CHRS) announced plans to shed as much as 30% of its workforce this year. The company said that layoffs began last week as it focuses on oncology drugs. Company announced divestment of its eye drug portfolio in Q4 2023.
Seeking Alpha · 03/14 15:22
Coherus BioSciences Price Target Maintained With a $13.00/Share by HC Wainwright & Co.
Dow Jones · 03/14 11:43
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $13 Price Target
Benzinga · 03/14 11:33
Analysts Conflicted on These Healthcare Names: Amedisys (AMED), Cytokinetics (CYTK) and Coherus Biosciences (CHRS)
Analysts have new ratings on Amedisys, Cytokinetics and Coherus Biosciences. Truist Financial analyst David Macdonald maintained a Hold rating on the Healthcare sector. The company’s shares closed at $93.25 today.
TipRanks · 03/14 11:30
Buy Rating Affirmed for Coherus Biosciences on Strong Sales and Strategic Restructuring
TipRanks · 03/14 10:15
BUZZ-Coherus falls after Q4 revenue misses estimates
Shares of cancer drug developer Coherus BioSciences fall 13% to $2.00 after the bell. Company reports revenue of $91.5 million in Q4. Company initiated a workforce cut of 30% on March 7. Analysts' average estimate for Q4 revenue was $96.4 million.
Reuters · 03/13 20:35
Coherus BioSciences Non-GAAP EPS of -$0.62 misses by $0.52, revenue of $91.5M beats by $1.07M
Coherus BioSciences' Q4 Non-GAAP EPS of -$0.62 misses by $0.52, revenue of $91.5M beats by $1.07M. Coherus is introducing a guidance range of combined 2024 R&D and SG&A expenses from $250 to $265 million.
Seeking Alpha · 03/13 20:12
Recap: Coherus BioSciences Q4 Earnings
Coherus BioSciences reported its Q4 earnings on March 13. The company missed its earnings estimate by $0.62. The firm's revenue was up $46.17 million from the same period last year. Coherus bioScience is expected to release its earnings Wednesday.
Benzinga · 03/13 20:05
*Coherus BioSciences: Introducing Guidance Range of Combined 2024 R&D and SG&A Expenses From $250M to $265M >CHRS
Dow Jones · 03/13 20:04
Coherus BioSciences Q4 2023 Adj EPS $(0.62) Misses $(0.12) Estimate, Sales $91.524M Miss $96.400M Estimate
Coherus BioSciences reported quarterly losses of $0.62 per share. The company reported quarterly sales of $91.524 million which missed the analyst consensus estimate of $96.400 million. Coherus also reported a 101.81 percent increase in sales over the same period last year.
Benzinga · 03/13 20:03
More
Webull provides a variety of real-time CHRS stock news. You can receive the latest news about Coherus Bioscien through multiple platforms. This information may help you make smarter investment decisions.
About CHRS
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.